cloudfront
  • info@reportsandmarkets.com
  • +44-020-3286-9338 (UK) | +1-214-736-7666 (US) | +1-740-994-0111 (US)
  • Sign In
  • Register

Report Detail



Pharma & HealthcareGlobal Tardive Dyskinesia (TD) Treatment Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

  • RnM2541248
  • |
  • 5 November, 2018
  • |
  • Global
  • |
  • 119 pages
  • |
  • GIR (Global Info Research)
  • |
  • Pharma & Healthcare

Tardive dyskinesia (TD) is a neurological disorder that has the involvement of the involuntary movements. The terms can be described as tardive which means delayed and dyskinesia which means abnormal movement. The symptoms of tardive dyskinesia include finger movement, facial grimacing, jaw swinging, repetitive chewing, continuous blinking of the eyes, tongue thrusting, and others. 

Scope of the Report:

The worldwide market for Tardive Dyskinesia (TD) Treatment is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

This report focuses on the Tardive Dyskinesia (TD) Treatment in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers

Teva Pharma

Biogen

Johnson & Johnson

GlaxoSmithKline

Neurocrine Biosciences

Pfizer

Novartis

Sanofi

AstraZeneca

Bayer AG

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Valbenazine

Amantadine

Tetrabenazine

Clonazepam

Others

Market Segment by Applications, can be divided into

Hospitals

Clinics

Others

There are 15 Chapters to deeply display the global Tardive Dyskinesia (TD) Treatment market.

Chapter 1, to describe Tardive Dyskinesia (TD) Treatment Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Tardive Dyskinesia (TD) Treatment, with sales, revenue, and price of Tardive Dyskinesia (TD) Treatment, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Tardive Dyskinesia (TD) Treatment, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Tardive Dyskinesia (TD) Treatment market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Tardive Dyskinesia (TD) Treatment sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source


Table of Contents

1 Market Overview

1.1 Tardive Dyskinesia (TD) Treatment Introduction

1.2 Market Analysis by Type

1.2.1 Valbenazine

1.2.2 Amantadine

1.2.3 Tetrabenazine

1.2.4 Clonazepam

1.2.5 Others

1.3 Market Analysis by Applications

1.3.1 Hospitals

1.3.2 Clinics

1.3.3 Others

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Teva Pharma

2.1.1 Business Overview

2.1.2 Tardive Dyskinesia (TD) Treatment Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Teva Pharma Tardive Dyskinesia (TD) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2 Biogen

2.2.1 Business Overview

2.2.2 Tardive Dyskinesia (TD) Treatment Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Biogen Tardive Dyskinesia (TD) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3 Johnson & Johnson

2.3.1 Business Overview

2.3.2 Tardive Dyskinesia (TD) Treatment Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Johnson & Johnson Tardive Dyskinesia (TD) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4 GlaxoSmithKline

2.4.1 Business Overview

2.4.2 Tardive Dyskinesia (TD) Treatment Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 GlaxoSmithKline Tardive Dyskinesia (TD) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5 Neurocrine Biosciences

2.5.1 Business Overview

2.5.2 Tardive Dyskinesia (TD) Treatment Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Neurocrine Biosciences Tardive Dyskinesia (TD) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.6 Pfizer

2.6.1 Business Overview

2.6.2 Tardive Dyskinesia (TD) Treatment Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Pfizer Tardive Dyskinesia (TD) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.7 Novartis

2.7.1 Business Overview

2.7.2 Tardive Dyskinesia (TD) Treatment Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Novartis Tardive Dyskinesia (TD) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.8 Sanofi

2.8.1 Business Overview

2.8.2 Tardive Dyskinesia (TD) Treatment Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Sanofi Tardive Dyskinesia (TD) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.9 AstraZeneca

2.9.1 Business Overview

2.9.2 Tardive Dyskinesia (TD) Treatment Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 AstraZeneca Tardive Dyskinesia (TD) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.10 Bayer AG

2.10.1 Business Overview

2.10.2 Tardive Dyskinesia (TD) Treatment Type and Applications

2.10.2.1 Product A

2.10.2.2 Product B

2.10.3 Bayer AG Tardive Dyskinesia (TD) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global Tardive Dyskinesia (TD) Treatment Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

3.1 Global Tardive Dyskinesia (TD) Treatment Sales and Market Share by Manufacturer (2016-2017)

3.2 Global Tardive Dyskinesia (TD) Treatment Revenue and Market Share by Manufacturer (2016-2017)

3.3 Market Concentration Rate

3.3.1 Top 3 Tardive Dyskinesia (TD) Treatment Manufacturer Market Share in 2017

3.3.2 Top 6 Tardive Dyskinesia (TD) Treatment Manufacturer Market Share in 2017

3.4 Market Competition Trend

4 Global Tardive Dyskinesia (TD) Treatment Market Analysis by Regions

4.1 Global Tardive Dyskinesia (TD) Treatment Sales, Revenue and Market Share by Regions

4.1.1 Global Tardive Dyskinesia (TD) Treatment Sales and Market Share by Regions (2013-2018)

4.1.2 Global Tardive Dyskinesia (TD) Treatment Revenue and Market Share by Regions (2013-2018)

4.2 North America Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

4.3 Europe Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

4.4 Asia-Pacific Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

4.5 South America Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

4.6 Middle East and Africa Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

5 North America Tardive Dyskinesia (TD) Treatment by Countries

5.1 North America Tardive Dyskinesia (TD) Treatment Sales, Revenue and Market Share by Countries

5.1.1 North America Tardive Dyskinesia (TD) Treatment Sales and Market Share by Countries (2013-2018)

5.1.2 North America Tardive Dyskinesia (TD) Treatment Revenue and Market Share by Countries (2013-2018)

5.2 United States Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

5.3 Canada Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

5.4 Mexico Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

6 Europe Tardive Dyskinesia (TD) Treatment by Countries

6.1 Europe Tardive Dyskinesia (TD) Treatment Sales, Revenue and Market Share by Countries

6.1.1 Europe Tardive Dyskinesia (TD) Treatment Sales and Market Share by Countries (2013-2018)

6.1.2 Europe Tardive Dyskinesia (TD) Treatment Revenue and Market Share by Countries (2013-2018)

6.2 Germany Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

6.3 UK Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

6.4 France Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

6.5 Russia Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

6.6 Italy Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

7 Asia-Pacific Tardive Dyskinesia (TD) Treatment by Countries

7.1 Asia-Pacific Tardive Dyskinesia (TD) Treatment Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific Tardive Dyskinesia (TD) Treatment Sales and Market Share by Countries (2013-2018)

7.1.2 Asia-Pacific Tardive Dyskinesia (TD) Treatment Revenue and Market Share by Countries (2013-2018)

7.2 China Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

7.3 Japan Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

7.4 Korea Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

7.5 India Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

7.6 Southeast Asia Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

8 South America Tardive Dyskinesia (TD) Treatment by Countries

8.1 South America Tardive Dyskinesia (TD) Treatment Sales, Revenue and Market Share by Countries

8.1.1 South America Tardive Dyskinesia (TD) Treatment Sales and Market Share by Countries (2013-2018)

8.1.2 South America Tardive Dyskinesia (TD) Treatment Revenue and Market Share by Countries (2013-2018)

8.2 Brazil Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

8.3 Argentina Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

8.4 Colombia Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

9 Middle East and Africa Tardive Dyskinesia (TD) Treatment by Countries

9.1 Middle East and Africa Tardive Dyskinesia (TD) Treatment Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa Tardive Dyskinesia (TD) Treatment Sales and Market Share by Countries (2013-2018)

9.1.2 Middle East and Africa Tardive Dyskinesia (TD) Treatment Revenue and Market Share by Countries (2013-2018)

9.2 Saudi Arabia Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

9.3 UAE Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

9.4 Egypt Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

9.5 Nigeria Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

9.6 South Africa Tardive Dyskinesia (TD) Treatment Sales and Growth Rate (2013-2018)

10 Global Tardive Dyskinesia (TD) Treatment Market Segment by Type

10.1 Global Tardive Dyskinesia (TD) Treatment Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global Tardive Dyskinesia (TD) Treatment Sales and Market Share by Type (2013-2018)

10.1.2 Global Tardive Dyskinesia (TD) Treatment Revenue and Market Share by Type (2013-2018)

10.2 Valbenazine Sales Growth and Price

10.2.1 Global Valbenazine Sales Growth (2013-2018)

10.2.2 Global Valbenazine Price (2013-2018)

10.3 Amantadine Sales Growth and Price

10.3.1 Global Amantadine Sales Growth (2013-2018)

10.3.2 Global Amantadine Price (2013-2018)

10.4 Tetrabenazine Sales Growth and Price

10.4.1 Global Tetrabenazine Sales Growth (2013-2018)

10.4.2 Global Tetrabenazine Price (2013-2018)

10.5 Clonazepam Sales Growth and Price

10.5.1 Global Clonazepam Sales Growth (2013-2018)

10.5.2 Global Clonazepam Price (2013-2018)

10.6 Others Sales Growth and Price

10.6.1 Global Others Sales Growth (2013-2018)

10.6.2 Global Others Price (2013-2018)

11 Global Tardive Dyskinesia (TD) Treatment Market Segment by Application

11.1 Global Tardive Dyskinesia (TD) Treatment Sales Market Share by Application (2013-2018)

11.2 Hospitals Sales Growth (2013-2018)

11.3 Clinics Sales Growth (2013-2018)

11.4 Others Sales Growth (2013-2018)

12 Tardive Dyskinesia (TD) Treatment Market Forecast (2018-2023)

12.1 Global Tardive Dyskinesia (TD) Treatment Sales, Revenue and Growth Rate (2018-2023)

12.2 Tardive Dyskinesia (TD) Treatment Market Forecast by Regions (2018-2023)

12.2.1 North America Tardive Dyskinesia (TD) Treatment Market Forecast (2018-2023)

12.2.2 Europe Tardive Dyskinesia (TD) Treatment Market Forecast (2018-2023)

12.2.3 Asia-Pacific Tardive Dyskinesia (TD) Treatment Market Forecast (2018-2023)

12.2.4 South America Tardive Dyskinesia (TD) Treatment Market Forecast (2018-2023)

12.2.5 Middle East and Africa Tardive Dyskinesia (TD) Treatment Market Forecast (2018-2023)

12.3 Tardive Dyskinesia (TD) Treatment Market Forecast by Type (2018-2023)

12.3.1 Global Tardive Dyskinesia (TD) Treatment Sales Forecast by Type (2018-2023)

12.3.2 Global Tardive Dyskinesia (TD) Treatment Market Share Forecast by Type (2018-2023)

12.4 Tardive Dyskinesia (TD) Treatment Market Forecast by Application (2018-2023)

12.4.1 Global Tardive Dyskinesia (TD) Treatment Sales Forecast by Application (2018-2023)

12.4.2 Global Tardive Dyskinesia (TD) Treatment Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source


captcha
Enter the code in the box:


captcha
Enter the code in the box:

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may not print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.


captcha
Enter the code in the box:



Summary:
Get latest Market Research Reports on Tardive Dyskinesia (TD) Treatment . Industry analysis & Market Report on Tardive Dyskinesia (TD) Treatment is a syndicated market report, published as Global Tardive Dyskinesia (TD) Treatment Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023. It is complete Research Study and Industry Analysis of Tardive Dyskinesia (TD) Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$3,480.00
$5,220.00
$6,960.00
2,336.82
3,505.23
4,673.64
3,202.30
4,803.44
6,404.59
421,567.20
632,350.80
843,134.40
230,770.63
346,155.95
461,541.26
Add To Cart Credit card Logo

Related Reports


Reason to Buy

Request for Sample of this report